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Clinical practice guidelines are being used in many countries 
throughout the world to improve the quality of patient care. 
The Dutch Orthopaedic Association has a long tradition of 
guideline development, starting in the mid-1980s with “emi-
nence-based consensus” and following in the mid-1990s the 
renewed calls for the establishment of international method-
ologies to promote the rigorous development of clinical guide-
lines and to assess their quality and their impact on practice. 
This updated guideline on total hip prosthesis was devel-
oped using the “Appraisal of Guidelines for Research and 
Evaluation (AGREE)” instrument (www.agreecollaboration.
org). 
Methods 
The process started with the formulation of current ques-
tions—both from the clinician’s and the patient’s point of 
view—by a steering group whose members were the authors 
of this paper.
Literature search
First, a general search was carried out for existing guidelines 
and systematic reviews. Afterwards, for each question the 
bibliographic databases PubMed and Embase were searched, 
using specific terms, to identify scientific literature published 
between 2000 and 2009. Studies published after January 1, 
2009 were not included unless they would alter the conclu-
sions. Reference lists of the retrieved studies were searched 
by hand for additional studies. The steering group was mainly 
interested in (systematic reviews of) randomized controlled 
trials (RCTs). If no RCTs were found, studies of a lower level 
of evidence were included.
Grading of study quality
After selection of relevant literature by the steering group, 
the studies were graded for quality and level of evidence by a 
methodologist and the members of the steering group (Table 
3, supplementary data). The criteria used are described in 
Table 1 (a systematic review of poor quality was downgraded 
Table 1. Grading of methodological quality of individual studies
Level of 
evidence 
Interventional studies Diagnostic accuracy studies  Harm, side effects,  etiology, prognosis 
A1  Systematic review / meta-analysis of at least 2 independently conducted studies of A2 level
A2  Randomized, double-blind trial 
with good study quality and 
a adequate number of study 
participants 
Indextest compared to reference test (reference 
standard); cut-offs were defined a priori; independ-
ent interpretation of test results; an adequate 
number of consecutive patients were enrolled; all 
patients received both tests.
Prospective cohort study of sufficient 
magnitude and follow-up, adequately 
controlled for ‘confounding’ and no 
selective follow-up. 
B  Clinical trial, but without all the 
features mentioned for level A2 
(including case-control study, 
cohort study).
Index test compared to reference test, but without 
all the features mentioned for level A2.
Prospective cohort study, but without 
all the features mentioned for level A2 
or retrospective cohort study or case-
control study. 
C  Non-comparative studies
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one level). For each question, the scientific evidence was sum-
marized in a conclusion with an accompanying level of evi-
dence (Table 2). 
For total hip replacement, the implant registries are an 
important source of information regarding outcome and fac-
tors influencing outcome. Many “population-based” registries 
meet the requirements of an A2 level of evidence (prospec-
tive cohort study of sufficient magnitude and follow-up, ade-
quately controlled for “confounding” and no selective follow-
up), and were graded as such.
Recommendations
Apart from the scientific evidence, recommendations are 
influenced by other considerations such as patient preferences, 
costs, availability of facilities, or organizational aspects. The 
recommendations for each question are based on the scientific 
evidence in combination with the most important consider-
ations. 
What are the indications and contraindications 
for total hip replacement?
Scientific evidence
Level 1: 
•	 Younger	patients	and	men	have	an	increased	risk	of	revision	
of their total hip prosthesis (Flugsrud et al. 2007, Santaguida 
et al. 2008).
•	 Improvement	 of	 postoperative	 function	 after	 total	 hip	
replacement is diminished at higher age (particularly in 
women) (Santaguida et al. 2008).
Level 2: 
•	 Postoperative	 complications	 (dislocation,	 infection,	 revi-
sion) occur more frequently with obesity (Flugsrud at al. 
2007,	Lübbeke	et	al.	2007,	Sadr	Azodi	et	al.	2008).
•	 Men	with	heavy	physical	activities	in	their	spare	time	have	
an	increased	risk	of	revision	of	the	acetabular	component	
(Flugsrud et al. 2007).
Level 3: 
•	 Poor	preoperative	mobility	and	function	do	not	influence	
postoperative pain (alleviation) (Röder et al. 2007).
•	 Obesity	does	not	influence	postoperative	pain	(alleviation),	
but reduces functional outcome (Busato et al. 2008).
Consideration. Based on demographic projection only, 
the number of total hip replacements in the Netherlands will 
increase from 20,715 in 2005 to 31,731 in 2030. Based on the 
continued trend, however, the number is expected to increase 
to 51,680 in 2005 (Otten et al. 2010). Furthermore, national 
and international differences in the incidence of total hip 
replacements due to osteoarthritis have been observed (Merx 
et	al.	2003,	Nationaal	Kompas	Volksgezondheid	2010).	This	
reflects the fact that the indication for hip replacement does not 
only depend on the incidence and prevalence of osteoarthritis, 
but is also influenced by other factors such as a more active 
lifestyle in the elderly, higher life expectancy, improved out-
comes of arthroplasties, changing reimbursement systems, 
etc. Thus, indications for total hip replacement differ around 
the world, and can only be given in general terms.
Recommendation. The indication for total hip replace-
ment should be based on pain, loss of function, radiographic 
changes,	and	failure	of	nonoperative	treatment.	Younger	age	
and obesity are relative contraindications. Delay of surgery in 
high age is not advisable in view of reduced functional out-
come and increased mortality. In addition, when progressive 
loss of function (with or without contractures) predominates 
over pain, surgery should not be delayed in view of reduced 
postoperative functional outcome.
What is the preferred type of prosthesis?
Different aspects of the total hip prosthesis are discussed sepa-
rately but cannot be evaluated independently from each other 
in a particular prosthesis type.
Cemented fixation vs. cementless fixation
Scientific evidence
Level 1:
•	 Several	cemented	and	cementless	femoral	prostheses	have	a	
proven favorable survival (> 90% after 10–15 years), but the 
survival of the acetabular component is not uniform. 
•	 Arthroplasty	registers	show	better	results	for	cemented	pros-
theses than for cementless prostheses, which is mainly due 
to inferior results of some cementless acetabular compo-
nents (National Joint Registry UK 2007, Australian Ortho-
paedic	Association	2008,	Mäkelä	et	al.	2008,	Norwegian	
Arthroplasty Register 2008).
Level 3:
•	 Expensive	prostheses	need	much	better	results	to	achieve	
economically cost-effective benefits, especially in patients 
aged	50–70	years	(Fitzpatrick	1998).
Considersation. The results for cementless prostheses are 
mostly based on studies in young patients. Comparable results 
are obtained if the factor age is adjusted for, although stud-
ies on cementless prostheses reveal more revisions for change 
of	the	polyethylene	liner	(Mäkelä	et	al	2008).	The	culture	of	
developing	and	marketing	new	hip	prostheses	reflects	a	high	
level of innovation and experimentation, but also commercial 
interests. An economically based study concluded that a new 
Table 2. Level of evidence of the conclusion 
Level  Conclusion based on 
1    A1 study or at least 2 independent studies of level A2.
2   1 study of level A2 or at least 2 independent studies of level B. 
3   1 study of level B or C. 
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prosthesis costs about 3 times more than a standard prosthe-
sis and is only cost-effective if the revision rate is reduced by 
about	40%	(Fitz	 patrick	et	al.	1998).
Recommendation. The choice of a total hip prosthesis, 
cemented or uncemented, must be based on peer-reviewed 
published studies with a follow-up of at least 10 years, and on 
the (direct and indirect) costs. New implants should be intro-
duced according to 4 steps: laboratory studies, small clinical 
series using radiostereometry, randomized studies compared 
with a well-documented prosthesis, and finally follow-up in 
an implant registry.
Head diameter
Scientific evidence
Level 1: 
•	 In	traditional	metal-on-polyethylene	articulations,	32-mm	
heads show higher wear rates than 22- or 28-mm heads after 
10 years of clinical use (Oparaugo et al. 2001, Tarasevicius 
et al. 2006).
Level 2: 
•	 The	incidence	of	posterior	dislocations	is	lower	in	32-mm	
heads than in 22- or 28-mm heads (Bystroem et al. 2003).
•	 Short-term	clinical	outcome	data	(up	to	5	years)	for	head	
diameters greater than 32 mm are comparable to the clinical 
outcome data for 22-, 28-, or 32-mm heads, but with lower 
dislocation rates within the first 3 months after surgery 
(Amstutz	et	al.	2004,	Cuckler	et	al.	2004,	Smith	et	al.	2005,	
Geller	et	al.	2006,	Peters	et	al.	2007,	Sikes	et	al.	2008).
Consideration. The reason for dislocation of a total hip pros-
thesis is multifactorial and related to the patient, the surgeon, 
the surgical approach, the type of prosthesis, and the head 
size. In traditional metal-on-polyethylene bearings, 32-mm 
heads have lower dislocation rates; however, the lowest wear 
rates are seen in 22-mm heads. To prevent dislocation, there 
is a trend toward larger head diameters, which is supported 
by	alternative	bearings	(metal	or	ceramic	on	crosslinked	poly-
ethylene, metal-on-metal, ceramic-on-ceramic) that are more 
wear-resistant. The outcome data up to 5 years for larger heads 
are comparable to those for head diameters of 32 mm or less, 
but long-term data are needed. Recently, there have been some 
concerns	about	the	claimed	wear	resistance	of	the	crosslinked	
polyethylenes in combination with with larger heads (Lachie-
wicz et al. 2009). Also, the theoretical advantage of larger 
heads is limited in practice because surgeons have the ten-
dency to place the larger cups too vertically (Crowninshield 
et al. 2004). 
Recommendation. More clinical and long-term evidence is 
needed to justify the standard use of larger-diameter heads. 
Heads larger than 32 mm should be restricted to patients with 
a	high	risk	of	dislocation.	Other	indications	are	preferably	
used in a clinical study setting. 
Bearing
Scientific evidence
Level 1: 
•	 The	 application	 of	 crosslinked	 polyethylene	 reduces	 the	
wear of polyethylene acetabular cups and inserts in the 
medium	term.	There	is	as	yet	no	evidence	that	crosslinking	
improves the survival rate of total hip prostheses (Triclot 
et	al.	2007,	Garcia-Rey	et	al.	2008,	Geerdink	et	al.	2009,	
McCalden	et	al.	2009,	Rajadhyaksha	et	al.	2009).
•	 The	 reduced	 wear	 of	 ceramic-on-polyethylene	 bearings	
in comparison to metal-on-polyethylene bearings is not 
reflected by improved clinical results in the medium term. 
(Kim 2005, Kraay et al. 2006). 
•	 Metal-on-metal	bearings	cause	increased	serum	levels	of	
metal ions (Brodner et al. 2003, Dahlstrand et al. 2009).
•	 The	 reduced	 wear	 of	 ceramic-on-ceramic	 bearings	 in	
comparison to other common bearings does not result in 
improved clinical results in the long term. (Bierbaum et al. 
2002, D’Antonio et al. 2005, Seyler et al. 2006, Capello et 
al. 2008, Lewis et al. 2010).
Consideration. The efficacy of various combinations of soft 
and hard bearing materials is commonly measured in terms of 
wear rate. Polyethylene acetabular components show less wear 
if small head diameters are used. Wear of polyethylene can 
also	be	reduced	by	the	use	of	crosslinked	polyethylene.	Hard	
material combinations such as metal-on-metal or ceramic-on-
ceramic rely on hydrodynamic lubrication. Their wear rate is 
less than that of polyethylene bearings, even if large-diame-
ter heads are used. One benefit of large head diameter is a 
reduced dislocation rate. The performance of hard bearings 
is dependent on component positioning. There is little evi-
dence for any clinical benefit of using hard bearing materials. 
Metal-on-metal bearings consistently show elevated serum 
levels of metal ions. In the Australian Orthopaedic Associa-
tion National Joint Replacement Registry (2008), metal-on-
polyethylene bearings have had a lower revision rate than all 
other combinations of bearing materials (after correction for 
age and sex).
Recommendation. A metal or ceramic head and a conven-
tional polyethylene acetabular cup or liner would be the first 
choice. Based on the medium-term reduced wear, a cross-
linked	polyethylene	cup	or	liner	can	be	considered.	There	is	
insufficient evidence to support the use of other types of bear-
ings, and we recommend that they should be used for investi-
gational purposes only.
What is the value of resurfacing hip 
arthroplasty?
Scientific evidence
Level 2:
•	 The	 short-term	 functional	 outcome	 of	 resurfacing	 hip	
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hip	arthroplasty	(Pollard	et	al.	2006,	Marker	et	al.	2009,	
Mont et al. 2009, Fowble et al. 2009, Lavigne et al. 2010, 
Stulberg et al. 2010).
•	 Resurfacing	 hip	 arthroplasty	 has	 some	 advantages	 over	
a conventional total hip replacement: a relatively higher 
activity score can be established and dislocations are rather 
uncommon. There is (still) no evidence that the bone-pre-
serving nature of the procedure is of clinically relevant ben-
efit in revisions (Pollard et al. 2006, Vail et al. 2006, Fowble 
et al. 2009, Mont et al. 2009, Lavigne et al. 2010).
•	 Resurfacing	hip	arthroplasty	has	clinically	relevant	disad-
vantages over conventional total hip replacement. Without 
proper patient selection, the early revision rates are higher 
than after a conventional total hip arthroplasty. The most 
frequent causes of revision are aseptic loosening, femoral 
neck	fracture,	and	adverse	reactions	to	metal-on-metal	par-
ticle release (Glyn-Jones et al. 2009, Grammatopolous et al. 
2009, Kahn et al. 2009, Prosser et al. 2010). 
Consideration. A good result with hip resurfacing depends 
on a combination of adequate patient selection, experience 
with the relatively complex surgical technique, and choice of 
implant. In the last few years, there has been increasing con-
cern about toxic effects of focal and systemic metal ion expo-
sure from these implants. A global decrease in the number of 
implanted resurfacing hip arthroplasties can be noted in the 
national registries. Only with a thoroughly performed long-
term follow-up—preferably in national implant registries—
will the true advantages and disadvantages of hip resurfacing 
in the young patient with osteoarthritis of the hip be elucidated. 
Recommendation. Resurfacing hip arthroplasty should be 
performed under close monitoring of the results and should be 
reserved for relatively young patients (below 60–65 years of 
age) with a femoral head diameter of greater than 50 mm and 
good	bone	stock.	Data	from	national	implant	registries	should	
dictate the choice of implant and the surgeon should have 
good experience of the relative complex surgical technique. 
What is the preferred surgical approach for total 
hip replacement?
Conventional procedures
Scientific evidence
Level 2:
•	 There	is	no	difference	in	postoperative	function	between	the	
posterolateral, the straight lateral, the anterolateral, and the 
anterior approaches to the hip (Masonis et al. 2002, Jolles et 
al. 2006, Kwon et al. 2006).
•	 The	straight	lateral	approach	gives	the	lowest	dislocation	
rate (Masonis et al. 2002, Jolles et al. 2006, Kwon et al. 
2006).
•	 Repair	of	the	capsule	diminishes	the	dislocation	rate	of	the	
posterolateral approach (Masonis et al. 2002, Kwon et al. 
2006).
Recommendation. There is no preference for any of the 4 
surgical approaches. Repair of the capsule is advised in the 
posterolateral approach. 
Minimally invasive procedures
Scientific evidence 
Level 1: 
•	 Minimally	 invasive	 total	 hip	 replacement	 has	 short-term	
advantages such as faster recovery and therefore shorter 
hospital stay (Mahmood et al. 2007, Verteuil et al. 2008, 
Wall et al. 2008, Chen et al. 2009).
Level 2:
•	 Minimally	invasive	hip	surgery	causes	more	muscle	damage	
and a cosmetically inferior (though smaller) scar (Mardones 
et al. 2005, Mow et al. 2005, Goldstein et al. 2008).
Level 3:
•	 The	 advantages	 of	 minimally	 invasive	 hip	 surgery	 are	
mainly	due	to	quicker	rehabilitation	and	better	postopera-
tive pain control (Nuelle et al. 2007).
Consideration. Many total hip prostheses with proven good 
long-term results are not suitable for minimally invasive hip 
surgery (MIS), so there is a tendency to use implants with-
out proven durability. The popularity of MIS is based on 
short-term advances such as shorter recovery time. Nuelle et 
al. (2007) concluded that patients operated by the traditional 
approach who had fast rehabitation programs recovered as 
quickly	as	patients	treated	by	MIS.	
Recommendation. Minimally invasive hip surgery should be 
restricted to controlled studies, as it is not yet clear whether 
the short-term advantages balance the possible long-term dis-
advantages.
What is the preferred method to prevent 
postoperative thromboembolic complications?
Scientific evidence
Level 1: 
•	 The	incidence	of	thromboembolic	complications	following	
total hip arthroplasty can be adequately reduced with low 
molecular weight heparins, fondaparinux, dabigatran, vita-
min K antagonists, and rivaroxaban. 
•	 Extended	 out-of-hospital	 thromboprophylaxis	 can	 further	
reduce the rate of venous thromboembolism following hip 
arthroplasty	(Eriksson	et	al.	2007,	2008,	Geerts	et	al.	2008,	
Kakkar	et	al.	2008).
Consideration. Several methods (mechanical and pharma-
cological) to reduce the incidence of venous thromboembo-
lism (VTE) are available. Mechanical methods are generally 
less effective than pharmacological thromboprophylaxis, and 
are cumbersome when used out of hospital. Thus, the use of 
pharmacological prophylaxis is advised except when a high 
risk	of	bleeding	precludes	the	use	of	pharmacological	agents.	
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a postoperative start of thromboprophylaxis regarding effi-
cacy	and	bleeding	risk.	A	preoperative	start	is	probably	more	
effective,	but	is	counterbalanced	by	an	increased	bleeding	risk	
(Strebel	et	al.	2002).	The	risk	on	VTE	continues	to	increase	
for a prolonged period, even after hospital discharge (White 
et al. 1998).
Recommendation.  Low molecular weight heparins, fon-
daparinux, dabigatran, vitamin K antagonists, or rivaroxa-
ban are effective means to prevent thrombosis after total hip 
replacement. Thromboprophylaxis can be initiated postopera-
tively	and	continued	for	4–5	weeks	after	surgery.	Adequate	
monitoring of side effects is advised when new anticoagulants 
(dabigatran, rivaroxaban) are used.
What prophylactic measures against 
infection should be used in primary total hip 
replacement? 
Systemic antibiotics
Scientific evidence
Level 1:
•	 Systemic	antibiotics	are	effective	in	the	prevention	of	deep	
and	superficial	infection,	with	a	relative	risk	reduction	of	
about 80% (AlBuhairan et al. 2008, Gillespie and Walen-
kamp	2010).
•	 There	is	no	difference	in	efficacy	between	first-	and	second-
generation cephalosporines (Albuhairan et al. 2008).
•	 Antibiotics	must	be	given	15–60	min	before	the	incision	
(Classen et al. 1992, Bowers et al. 1973, Kasteren et al. 
2007, Stefansdóttir et al. 2009, Steinberg et al. 2009).
•	 The	maximum	duration	of	antiobiotic	prophylaxis	is	24	h	
(AlBuhairan	et	al.	2008,	Gillespie	and	Walenkamp	2010).
Level 4:
•	 In	cases	of	high	risk	of	MRSA	(as	in	carriers),	a	glycopep-
tide (teicoplanin or vancomycin) should be used (Soriano et 
al. 2006, Meehan et al. 2009).
Antibiotic-loaded bone cement
Scientific evidence
Level 2: 
•	 In	cemented	prostheses,	the	use	of	antibiotic-loaded	bone	
cement has a prophylactic effect on deep infections. The rate 
of “aseptic” loosening is also reduced, possibly by reduction 
of low-grade infections (Josefsson et al. 1993, Espehaug et 
al. 1997, Malchau et al. 1998, Parvizi et al. 2008).
•	 The	incidence	of	superficial	wound	infections	is	not	reduced	
by antibiotic-loaded bone cement; prophylaxis with sys-
temic antibiotics remains necessary (Josefsson et al. 1993).
•	 Prophylactic	administration	of	systemic	antibiotics	and	anti-
biotic-loaded	bone	cement	reduce	the	risk	independently	
and can be combined (multiplied) (Espehaug et al. 1997, 
Persson et al. 1999, Engesaeter et al 2003).
Air-handling systems
Scientific evidence
Level 1:
•	 When	prostheses	are	implanted,	the	air	supplied	at	the	operat-
ing area and the instrument tables must contain less than 10 
cfu bacteria per m3 (Lidwell et al. 1982, Malchau et al. 1993).
Consideration. Antibiotics are the most effective prophylac-
tic	measure	for	prevention	of	infection.	The	risk	reduction	is	
75–80%. They must be active against the most frequent caus-
ative bacteria: S. aureus and S. epidermidis. The maximum 
duration of the prophylaxis is 24 h. Whether or not 1 dose is 
sufficient is debated. In prosthesis implantation, a duration of 
12–24 h seems better, also since postoperative pneumonia and 
urinary tract infection are reduced, as well as aseptic loosen-
ing (Wymenga et al. 1992, Engesaeter et al. 2003, Gillespie 
and	Walenkamp	2010).	When	antibiotics	are	administered	too	
late, the tissue concentration will be too low; given too early, 
the antibiotic concentration will be too low at the end of the 
operation—especially for antibiotics with a short half-life.
Antibiotic-loaded bone cement has a protective effect by 
release of the antibiotic from the surface. In animal experi-
ments,	this	prophylaxis	is	effective	6	weeks	postoperatively	
(Elson et al. 1977, Blomgren 1981), so it protects against both 
peroperative contamination and early postoperative bactere-
mia that may cause hematogenous infection. In general, the 
commercially available bone cements—often using gentami-
cin—are effective. 
Prevention of contamination of the wound is the most 
effective and logical measure. There is a direct relationship 
between the amount of bacteria in the air and the deep infec-
tion rate (Lidwell et al. 1982). In prevention of contamination, 
other measures such as occlusive clothing and strict discipline 
regarding hygiene are equally important, but they cannot com-
pete with the effect of uncontaminated air. Clean air reduces 
bacterial contamination of the wound, and has proven to be 
highly effective. The best choice is a laminar downflow dis-
placement ventilation system with a large plenum (3 × 3 
m2), an air inflow speed of 35 cm/sec, and with the inlet air 2 
degrees colder than the outlet air.
General prophylactic measures are assumed to be applied—
such as disinfection, occlusive clothing, strict discipline, and 
optimal surgical technique (Knobben et al. 2006). Systemic 
antibiotics,	local	antibiotics,	and	clean	air	reduce	the	risk	of	
infection by 80%, 50%, and 50% respectively, and they act 
independently of each other (Lidwell et al. 1987). These 
means	of	reduction	of	infection	risk	can	be	combined,	how-
ever (Persson et al. 1999). 
Recommendation. In all primary total hip replacements, sys-
temic antibiotic prophylaxis is advisable, with first- or second-
generation cephalosporines started 15–60 min before incision 
and continued for 24 h at most, and when cemented in combi-
nation with the use of antibiotic-loaded bone cement. Further-
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displacement ventilation system that is capable of maintaining 
bacterial counts of less than 10 cfu/m3 in the operation field.
How does one prevent hematogenous infection 
of prostheses?
Scientific evidence
Level 2:
•	 Hematogenic	 infections	 of	 prostheses	 occur	 mainly	 in	
patients with reduced immunity, especially rheumatoid 
arthritis,	and	particularly	in	cases	of	skin	infection	in	the	
same leg (Deacon et al. 1996, Kaandorp 1998, Krijnen et al. 
2001).
•	 Patients	with	an	active	infection	in	their	body	have	a	higher	
risk	of	prosthetic	infection	(Ainscow	et	al.	1984,	Deacon	et	
al, 1996, Waldman et al 1997, Kaandorp 1998, Krijnen et al. 
2001).
Level 3:
•	 Antibiotic	prophylaxis	in	dental	procedures	is	only	useful	
when these procedures are performed on infected tissue 
(Gillespie 1990, Krijnen et al. 2001).
Consideration. Bacteremia is common, but may only cause 
hematogenous infection of the prosthesis when the bacterial 
load is high and the bacteria are virulent. The most frequent 
causes	 are	 skin	 infections	 (Deacon	 et	 al.	 1996,	 Kaandorp	
1998). Advisory committees in several countries came to the 
same conclusion: only give antibiotic prophylaxis in dental 
treatment	when	performed	in	an	infected	region	(Uçkay	et	al.	
2008).
Recommendation. Prophylactic antibiotics (e.g. 1,250 mg 
amoxicilline/clavulanic acid) should be given in all invasive 
procedures in patients with reduced immunity, in dental pro-
cedures in infected tissue, in endoscopy and cystoscopy in 
symptomatic infections, and in esophagoscopy.
What is the preferred anesthetic technique for 
total hip replacement?
Scientific evidence 
Level 1:
•	 Less	postoperative	pain	is	experienced	after	regional	anes-
thesia than after general anesthesia (MacFarlane et al. 2009, 
Choi et al. 2009).
•	 Blood	loss	and	the	incidence	of	venous	thrombosis	are	not	
different in regional and general anesthesia (Mauermann et 
al. 2006, MacFarlane et al. 2009, Choi et al. 2009, Hu et al. 
2009).
Level 1–2:
•	 Neuraxial	anesthesia	(spinal	or	epidural)	results	in	urinary	
retention and hypotension more often than does general 
anesthesia (Choi et al. 2009).
Consideration. Regional techniques consist of neuraxial 
analgesia	or	peripheral	nerve	blockade.	The	duration	of	sur-
gery, length of hospital stay, cardiopulmonary morbidity, inci-
dence of thromboembolic events, cognition and blood loss 
were no different in either of the techniques used compared 
with general anesthesia. Pain, nausea, and vomiting were 
reduced in patients who had undergone regional techniques. 
Recommendation. Regional anesthetic techniques are to be 
preferred, based on better quality of postoperative analgesia. 
When	neuraxial	anesthesia	is	used,	urinary	retention	is	a	risk;	
this can be effectively reduced through the use of a urinary 
catheter after surgery. 
What is the value of physiotherapy?
Scientific evidence
Level 2: 
•	 Physiotherapy	after	total	hip	replacement	is	effective	for	
recovery of strength, physical function, and stability (Suetta 
et al. 2004, Trudelle et al. 2004, Maire et al. 2006, Galea et 
al. 2008). 
•	 Physiotherapy	 before	 total	 hip	 replacement	 is	 not	 effec-
tive for recovery of physical function and reduction of pain 
(Gocen	et	al.	2004,	Rooks	et	al.	2006,	Ferrara	et	al.	2008).
•	 Clinical	pathways	in	total	hip	replacement	are	cost-effective,	
while functional outcomes and complications are compara-
ble (Kim et al. 2003, Brunenberg et al. 2005, Siggeirsdottir 
et al. 2005, Larsen et al. 2008).
Consideration.	 Generally	 speaking,	 preoperative	 exercise	
is	not	effective,	but	because	poor	function	is	a	risk	factor	for	
poor recovery after total hip replacement, preoperative train-
ing may be considered in (older) dependent patients with 
poor function. During hospital stay, postoperative rehabilita-
tion	after	total	hip	replacement	is	aimed	at	quick	mobiliza-
tion guided by local hospital protocols. After discharge from 
the hospital, postoperative physiotherapy is continued with 
the purpose of counteracting physical dysfunction, reduced 
strength, and reduced mobility, and to reach the patient’s opti-
mal function. There have been a few random controlled trials 
that studied the effects of postoperative exercise programs 
after total hip replacement. All the trials compared different 
supervised (home) exercise programs and found that they had 
effects on strength and physical function. So, postoperative 
physiotherapy is indicated in patients with total hip replace-
ment in order to follow a supervised (home) exercise program 
that is based on the patient’s dysfunctions. Clinical pathways 
are cost-effective, with comparable clinical outcomes and 
complications, but it is not clear whether group-oriented reha-
bilitation is better.
Recommendation. Preoperative physiotherapy (including 
advice	and	support	in	cane	walking)	may	be	considered	only	
in older, dependent people with poor physical function. Post-
operative physiotherapy is recommended, including a post-
discharge supervised (home) exercise program that is based Acta Orthopaedica 2011; 82 (5): 567–576  573
on the patient’s dysfunctions in strength, physical function, 
and mobility. Complete care in total hip replacement is pref-
erably given as clinical pathway with preoperative education 
about	fast	track	aspects,	individual	advice	and	support,	and	
postoperative rehabilitation. 
Is there a need for routine follow-up after total 
hip replacement?
Scientific evidence 
Level 3: 
•	 There	is	no	need	for	routine	follow-up	between	1	and	5	
years after total hip replacement (Röder et al. 2003, King et 
al. 2004).
Consideration. Monitoring of patients shortly after the oper-
ation concentrates on healing of the wound and on recovery 
of	function.	Broadly	speaking,	this	stage	is	complete	1	year	
after surgery, including the fixation of an uncemented prosthe-
sis. After the first year, routine follow-up is directed at detec-
tion of complications such as polyethylene wear or osteolysis, 
and deterioration of function. By being followed up routinely 
every 1, 2, or 3 years, patients get used to regular follow-up at 
a later stage. Furthermore, it can be important for an (inexpe-
rienced)	orthopedic	surgeon	to	know	the	results	of	his/her	own	
work	(quality	control).	This	is	only	possible	by	regular	clinical	
and radiological monitoring of his or her own patients. 
Recommendation. Routine follow-up should be carried out 
at least during the first year and after the fifth year, or earlier 
if the surgeon considers it necessary—based on experience of 
the prosthesis used. 
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